In a previous study (B. P. Lockhart, H. Tsiang, P. E. Ceccaldi, and S. Guillemer, Antiviral Chem. Chemother. 2:9-15, 1991), we demonstrated an antiviral effect of the general anesthetic ketamine for rabies virus in neuronal cultures and in rat brain. This report describes an attempt to determine at what level ketamine acts on the rabies virus cycle in rat cortical neuron cultures. Immunofluorescence and [35S]methionine labelling of infected neurons showed that ketamine (1 to 1.5 mM) inhibited viral nucleoprotein and glycoprotein syntheses. Northern (RNA) blots of total RNA from drug-treated neurons, hybridized with 32P-labelled oligonucleotide probes for rabies virus nucleoprotein, matrix protein, and glycoprotein genes, showed a marked reduction (5-to 11-fold) in the levels of rabies virus mRNAs, relative to those in untreated neurons. No significant change in the levels of cellular 13-actin mRNA were detected in ketamine-treated cells.A similar antiviral effect was observed with MK-801; however, no inhibition of rabies virus synthesis was observed with the general anesthetic chloral hydrate. The antiviral effect was not complete; a time-dependent recovery of viral transcription and rabies virus protein synthesis was observed, but no infectious virus was released into the culture supernatant. The lack of any modification of cellular protein or mRNA synthesis by ketamine suggests an antiviral mechanism acting at the level of rabies virus genome transcription.Rabies virus, a member of the Rhabdoviridae family, contains an unsegmented negative-stranded RNA genome that codes sequentially for five proteins: nucleoprotein N, phosphoprotein M1, matrix protein M2, glycoprotein G, and RNA-dependent RNA polymerase L (29). The virus is highly neurotropic (38) and produces dramatic clinical symptoms leading invariably to death (12). Despite widespread and effective vaccination programs, rabies is still believed responsible for up to 20,000 human fatalities per year (35). The classical postexposure treatment for rabies infection consists of vaccination and, in cases of severe and advanced exposure, vaccination is combined with immunotherapy with either equine or human antirabies immunoglobulins (37). However, the limited availability of serum, combined with the potential risk of hepatitis B and human immunodeficiency virus contamination from human sera, has restricted its application and partly contributed to failures of postexposure treatment for rabies (2,6,36). It is for these reasons as well as for the lack of efficient anti-rabies virus agents (8, 11) that we were prompted to assess alternative potential drugs for effective postexposure treatment for rabies.We previously showed that the dissociative anesthetic ketamine, a noncompetitive antagonist of the N-methyl-Daspartate (NMDA) receptor, inhibited the production (100-to 1,000-fold) of rabies virus in a dose-dependent manner and that the inhibitory effect was unrelated to any mechanism operating through high-affinity NMDA receptor sites (20). The antiviral effect was...